U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509112) titled 'Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study' on March 24.
Brief Summary: Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for ...